Parliamentary Search

Estimates day on Thursday, 8 December 2005, in the House of Commons, led by Kevin Barron. The answering member was Liam Byrne.

Department of Health

Vote on Account 2006-07. First estimates day. Motion that, for the year ending with 31st March 2007, for expenditure by the Department of Health— (1) resources, not exceeding £27,595,662,000, be authorised, on account, for use as set out in HC 465, and (2) a sum, not exceeding £26,808,818,000, be granted to Her Majesty out of the Consolidated Fund, on account, to meet the costs as so set out. Question deferred. Resolved.

Secondary information

Type
Parliamentary proceeding
Reference
440 c1021-77 
Session
2005-06
Department
Department of Health
Procedure
Supply estimates
Chamber / Committee
House of Commons chamber
Related items
Estimates
Thursday, 1 December 2005
Parliamentary proceedings
House of Commons
Vote on account 2006-07
Thursday, 8 December 2005
Parliamentary proceedings
House of Commons
Show all related items (6)
Proceeding contributions
Brian Iddon | 440 c1061 (Link to this contribution) Does the hon. Gentleman agree that the take-up of cancer drugs would be even slower if we did not be...
Brian Iddon | 440 c1048 (Link to this contribution) Pharmacists often do not know where the box has come from. Last night, we were shown a trick that th...
Show all contributions (78)
Brian Iddon | 440 c1047-8 (Link to this contribution) I agree. I am suggesting that criminal entrepreneurs have now entered the parallel trading market. L...
Brian Iddon | 440 c1039 (Link to this contribution) : My hon. Friend paints a very black picture indeed of the pharmaceutical industry. I cannot deny th...
Brian Iddon | 440 c1040 (Link to this contribution) So will my hon. Friend admit that scientists throughout the pharmaceutical industry are acting purel...
Brian Iddon | 440 c1034 (Link to this contribution) I must challenge that statement. Evidence was given at a meeting in the House last night that packag...
Brian Iddon | 440 c1061 (Link to this contribution) That is the very reason for the controversial move of the National Institute for Medical Research fr...
Brian Iddon | 440 c1023 (Link to this contribution) Does my right hon. Friend agree that counterfeit drugs are an increasing problem and that many count...
Julia Goldsworthy | 440 c1032 (Link to this contribution) I was not aware of that. I am not sure how the ABPI could provide flights to and from seminars at th...
Julia Goldsworthy | 440 c1034 (Link to this contribution) I thank the hon. Gentleman for his intervention. We support many of the recommendations outlined in ...
Julia Goldsworthy | 440 c1034 (Link to this contribution) I thank the hon. Gentleman for his point. I was just coming to that. The issue is not simply a quest...
Julia Goldsworthy | 440 c1033-4 (Link to this contribution) I think that the hon. Gentleman is right. What will happen once the funding structure changes and wh...
Julia Goldsworthy | 440 c1033 (Link to this contribution) It is of course important to make such drugs available as quickly as possible, but certain systemic ...
Julia Goldsworthy | 440 c1032-3 (Link to this contribution) I recognise the hon. Gentleman’s concerns, but of course, although the problems associated with pati...
Julia Goldsworthy | 440 c1030-2 (Link to this contribution) I should like to declare an interest in that I have a slight cold at the moment, so I am probably be...
Adam Afriyie | 440 c1055-6 (Link to this contribution) It is a pleasure to participate in this debate. We should be thankful to the pharmaceutical industry...
Paul Flynn | 440 c1057 (Link to this contribution) Is the hon. Gentleman aware that Eliot Spitzer in New York took GlaxoSmithKlein to court and the com...
Lord Lansley | 440 c1057-61 (Link to this contribution) I understand the point that the hon. Gentleman has been making and I do not doubt his long history o...
Paul Flynn | 440 c1051 (Link to this contribution) Does the hon. Gentleman believe that, given the problems with Vioxx, which is just one of the COX-2 ...
Lord Lansley | 440 c1054 (Link to this contribution) Let us give credit where it is due. The World Health Organisation has instituted the global campaign...
Richard Taylor | 440 c1051-4 (Link to this contribution) I agree absolutely with the hon. Gentleman, and I shall deal with another point relating to COX-2 in...
Charles Walker | 440 c1054-5 (Link to this contribution) I am grateful for the opportunity to speak in this important debate. I thought that I would need to ...
Richard Taylor | 440 c1054 (Link to this contribution) I am aware of that and I agree. The Government somehow have to balance the needs of patient safety ...
Richard Taylor | 440 c1048-9 (Link to this contribution) I should like to start by echoing the comments of the hon. Member for Southend, West (Mr. Amess), wh...
Ian Gibson | 440 c1048 (Link to this contribution) Is my hon. Friend saying that pharmacists do not know where the pills have come from? Do they simply...
Ian Gibson | 440 c1049 (Link to this contribution) Did the Committee’s study of research reach any conclusion on the merger mania in the pharmaceutical...
Richard Taylor | 440 c1049-51 (Link to this contribution) I do not think that there was any hard evidence that that merger had produced an increase in researc...
Charles Walker | 440 c1047 (Link to this contribution) Is the hon. Gentleman aware that organised criminals are moving into this field because it is more l...
David Amess | 440 c1045 (Link to this contribution) I like where my hon. Friend is leading me and was aware of his interest in the matter. The Minister ...
Lord Lansley | 440 c1044-5 (Link to this contribution) Does my hon. Friend agree that although this matter is not covered in the Health Committee report, t...
Ian Gibson | 440 c1043 (Link to this contribution) Is the hon. Gentleman aware that a Sheffield university lecturer was sacked because, although he was...
David Amess | 440 c1043-4 (Link to this contribution) The House will have heard what the hon. Gentleman said. It is a valuable intervention, which I know ...
Paul Flynn | 440 c1040 (Link to this contribution) I agree entirely; we could continue to record such successes at great length. Indeed, I think in my ...
Paul Flynn | 440 c1040 (Link to this contribution) I am not sure whether my hon. Friend was present earlier, but I tried to make that distinction when ...
Paul Flynn | 440 c1035-8 (Link to this contribution) I believe that this report is among the three best that I have seen in my 20 years in Parliament. I ...
Paul Flynn | 440 c1038-9 (Link to this contribution) We all hope so. Like many, I thought that having a rational and genuinely independent body to look a...
Adam Afriyie | 440 c1034 (Link to this contribution) I apologise to the hon. Lady for pressing her in her ill health, but can she be clear about what sol...
Adam Afriyie | 440 c1033 (Link to this contribution) : I thank the hon. Lady for giving way before she moves to her final, final point. She focused on co...
Paul Flynn | 440 c1032 (Link to this contribution) : The new code of practice is entirely cosmetic and has been described by the British Medical Associ...
Lord Lansley | 440 c1076 (Link to this contribution) I have not suggested getting rid of the PPRS either, but irrespective of whether the right hon. Gent...
Kevin Barron | 440 c1076-7 (Link to this contribution) If the OFT drives that, it will happen. The report suggested that the Department of Trade and Indust...
Kevin Barron | 440 c1073-4 (Link to this contribution) With the leave of the House, I wish to reply to the debate. I thought that the Whips had more influe...
Lord Lansley | 440 c1074 (Link to this contribution) Doctors attend many industry-sponsored conferences, meetings, dinners and events, including those su...
Kevin Barron | 440 c1074-5 (Link to this contribution) That is my experience as well. I declared that I am a lay member of the General Medical Council, th...
Speaker | 440 c1073 (Link to this contribution) Order. The right hon. Gentleman should ask for the leave of the House to reply to the debate.
Liam Byrne | 440 c1073 (Link to this contribution) No, I must conclude, because I know that my right hon. Friend the Member for Rother Valley is waitin...
Lord Lansley | 440 c1073 (Link to this contribution) If we are going to break the consensus, I shall ask the Minister this question. The Prime Minister a...
Liam Byrne | 440 c1073 (Link to this contribution) I am sorry to see that the consensus has collapsed as quickly as a soufflé. I do not have the precis...
Lord Lansley | 440 c1061-6 (Link to this contribution) The hon. Gentleman keeps touching a raw nerve. I have corresponded with the Medical Research Council...
Liam Byrne | 440 c1066-73 (Link to this contribution) I am grateful for the opportunity to respond to this excellent debate. I, too, congratulate former a...
Lord Lansley | 440 c1061 (Link to this contribution) Indeed. I have had the benefit of visiting the Christie hospital to see how translational research a...
Peter Bone | 440 c1022 (Link to this contribution) It has come to light that one of the problems is repeat prescription provision, especially in the ca...
Kevin Barron | 440 c1022 (Link to this contribution) That is correct—and in doing so, the amount of money that the industry makes in exporting around the...
Philip Hollobone | 440 c1022 (Link to this contribution) I congratulate the right hon. Gentleman on his introductory remarks. He is absolutely right to place...
Kevin Barron | 440 c1021 (Link to this contribution) First, I declare an interest in that I am currently a lay member of the General Medical Council and ...
Kevin Barron | 440 c1022 (Link to this contribution) Repeat prescriptions are sometimes numerically limited so that one has one, four or five out of six....
Kevin Barron | 440 c1023 (Link to this contribution) I am not aware of the Liverpool report, but my hon. Friend is right about what the Government mentio...
Paul Flynn | 440 c1023 (Link to this contribution) The university of Liverpool recently reported that there are at least 10,000 fatal adverse reactions...
Kevin Barron | 440 c1023 (Link to this contribution) I agree with my hon. Friend. Although the report did not look into the matter in detail, parallel tr...
Kevin Barron | 440 c1023-4 (Link to this contribution) I agree with the hon. Gentleman. There should be more ongoing studies to establish what happens afte...
Lord Lansley | 440 c1023 (Link to this contribution) Does the right hon. Gentleman agree that we should not assume that randomised control trials designe...
Kevin Barron | 440 c1024 (Link to this contribution) I do not disagree with the hon. Gentleman, but I shall not be tempted to discuss information technol...
Lord Lansley | 440 c1024 (Link to this contribution) This is an interesting point, and I hope that the Minister will tell us more about electronic prescr...
Paul Flynn | 440 c1024 (Link to this contribution) A serious situation has just been revealed in a report by the university of Sussex, which shows that...
Charles Walker | 440 c1032 (Link to this contribution) Am I not right in thinking that the new ABPI code of conduct specifically limits the maximum value o...
Kevin Barron | 440 c1027-30 (Link to this contribution) I do not disagree with that, and I do not think that anyone else would either, although obviously th...
Lord Lansley | 440 c1027 (Link to this contribution) Does the right hon. Gentleman agree that we must be careful about criticising what are described as ...
Kevin Barron | 440 c1026-7 (Link to this contribution) Yes, it does. It should concern us all, and it should concern the pharmaceutical industry more than ...
Adam Afriyie | 440 c1026 (Link to this contribution) I thank the right hon. Gentleman for being so generous in giving way. It seems that the National In...
Kevin Barron | 440 c1025-6 (Link to this contribution) Vioxx is an issue for everyone here, and the Health Committee asked for a public inquiry into the ma...
Paul Flynn | 440 c1024-5 (Link to this contribution) I want to give the House a clear example of the disastrous failure of our regulatory system. The F...
Kevin Barron | 440 c1024 (Link to this contribution) My hon. Friend will have to forgive me, because I disagree with parts of what he has just said. I kn...
Lord Lansley | 440 c1056-7 (Link to this contribution) This has been a very good debate, and I am delighted to have had the opportunity both to listen and ...
Brian Iddon | 440 c1045-7 (Link to this contribution) I have not come prepared to give a speech, but I should like to comment briefly on patient safety. I...
David Amess | 440 c1040-3 (Link to this contribution) The hon. Member for Newport, West (Paul Flynn) has strong views on these issues. He and I have discu...
Lord Lansley | 440 c1033 (Link to this contribution) : We have not heard the hon. Lady’s proposal on Herceptin. On the face of it, Herceptin has signific...
Adam Afriyie | 440 c1038 (Link to this contribution) : The hon. Gentleman is making a powerful case. NICE does a good job, but is he confident that it wi...
Subjects
Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
Link
View this Parliamentary proceeding on www.publications.parliament.uk